Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,953 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: tanaka m, tanaka y. Hepatol Res. 2023 Feb;53(2):116-126. doi: 10.1111/hepr.13852. Epub 2022 Nov 16. Hepatol Res. 2023. PMID: 36316794
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.
Sugimoto R, Satoh T, Ueda A, Senju T, Tanaka Y, Yamashita S, Koyanagi T, Kurashige T, Higuchi N, Nakamura T, Tanaka M, Azuma Y, Ohno A, Ooho A, Ooe M, Mutsuki T, Uchimura K, Kuniyoshi M, Tada S, Aratake Y, Yoshimoto T, Yamashita N, Harada S, Nakamuta M, Motomura K, Kohjima M; Liver disease Investigators’ Network of Kyushu University & Surrounding Hospitals (LINKS). Sugimoto R, et al. Among authors: tanaka m, tanaka y. Medicine (Baltimore). 2022 Oct 7;101(40):e30871. doi: 10.1097/MD.0000000000030871. Medicine (Baltimore). 2022. PMID: 36221372 Free PMC article.
Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma.
Sugimoto R, Inada H, Tanaka Y, Senju T, Aratake Y, Nakanishi A, Miki M, Lee L, Hisano T, Matsumoto Y, Mano Y, Iguchi T, Sugimachi K, Okumura Y, Taguchi K, Furukawa M. Sugimoto R, et al. Among authors: tanaka y. Clin J Gastroenterol. 2021 Oct;14(5):1484-1490. doi: 10.1007/s12328-021-01470-y. Epub 2021 Jun 27. Clin J Gastroenterol. 2021. PMID: 34176067 Free PMC article.
Risk factors for de novo hepatitis B during solid cancer treatment.
Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Sugimoto R, et al. Among authors: tanaka y. World J Clin Cases. 2020 Dec 26;8(24):6264-6273. doi: 10.12998/wjcc.v8.i24.6264. World J Clin Cases. 2020. PMID: 33392307 Free PMC article.
Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
Okumura Y, Kohashi K, Tanaka Y, Kato M, Maehara Y, Ogawa Y, Oda Y. Okumura Y, et al. Among authors: tanaka y. Virchows Arch. 2020 Jun;476(6):881-890. doi: 10.1007/s00428-019-02741-3. Epub 2020 Jan 11. Virchows Arch. 2020. PMID: 31927624
14,953 results
You have reached the last available page of results. Please see the User Guide for more information.